MARKET

BLCO

BLCO

Bausch + Lomb Corporation
NYSE
14.76
-0.14
-0.94%
After Hours: 15.26 +0.5 +3.39% 17:14 04/25 EDT
OPEN
14.71
PREV CLOSE
14.90
HIGH
14.95
LOW
14.70
VOLUME
251.28K
TURNOVER
0
52 WEEK HIGH
21.95
52 WEEK LOW
13.62
MARKET CAP
5.18B
P/E (TTM)
-19.8975
1D
5D
1M
3M
1Y
5Y
Bausch + Lomb reports positive study results for Blink NutriTears
Bausch + Lomb reports positive study results for Blink NutriTears. The eyecare company plans to launch the product in the US in early Q3. The study met primary endpoints of change in tear production and participant reports of dry eye symptoms. Bausch and Lomb was spun out of BHC in 2022.
Seeking Alpha · 12h ago
Bausch + Lomb’s Breakthrough in Dry Eye Relief
TipRanks · 15h ago
BRIEF-Bausch + Lomb Announces Statistically Significant Results From Clinical Study Of Novel Daily Nutritional Supplement
Bausch + Lomb Announces Statistically Significant Results From Clinical Study Of Novel Daily Nutritional Supplement for dry eyes. Study found Nutritional supplement to be well-tolerated. No serious adverse events were reported from the clinical study, Bausch and Lomb says.
Reuters · 15h ago
Bausch + Lomb Announces Results From A Clinical Study Of A Novel Daily Nutritional Supplement For Dry Eyes, All Primary Endpoints Achieved
Novel Supplement Shown to Address Signs and Symptoms of Dry Eyes, all Primary Endpoints Achieved. Bausch + Lomb expects to launch the supplement under the brand name Blink NutriTears in the third quarter of 2024 in the U.S. The study met both of its primary endpoints. Dry eyes are a prevalent ocular surface disorder.
Benzinga · 16h ago
BAUSCH + LOMB CORP: NUTRITEARS WAS FOUND TO BE WELL-TOLERATED
Reuters · 16h ago
Analysts Estimate Bausch + Lomb (BLCO) to Report a Decline in Earnings: What to Look Out for
NASDAQ · 1d ago
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Bausch + Lomb Corporation (BLCO)
TipRanks · 1d ago
RBC Capital Maintains Outperform on Bausch & Lomb, Lowers Price Target to $18
Benzinga · 3d ago
More
About BLCO
Bausch + Lomb Corporation is a Canada-based global eye health company. The Company’s Vision Care segment includes both a contact lens business and a consumer eye care business that consists of contact lens care products, over the counter (OTC) eye drops and eye vitamins. The Company’s Ophthalmic Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Its Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. The Company’s brands include PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, and many more.

Webull offers Bausch + Lomb Corp stock information, including NYSE: BLCO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BLCO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BLCO stock methods without spending real money on the virtual paper trading platform.